Ga naar de inhoud
  • Countries
    • Czech Republic
    • Finland
    • France
    • Germany
    • Greece
    • Italy
    • Ireland
    • Japan
    • Netherlands
    • Poland
    • Spain
    • Switzerland
    • United Kingdom
    • USA
  • Partners
    • VPAGs
      • AEVASI
      • AIVA
      • APACS
      • Association Takayasu France
      • ELEANA
      • France Vascularites
      • Kosapo
      • SHG Frankfurt am Main
      • SHG Mainz
      • SHG Würzburg-Nürnberg
      • VASAS – Switzerland
      • Vasculitis Foundation
      • Vasculitis Netherlands
      • Vasculitis Poland
      • Vasculitis UK
      • Vaskuliittiyhdistys ry
      • Vaskulitida.cz
      • Vaskulitis e.V.
      • VIA
    • Hospitals
    • Institutions
  • Projects
    • Overview Projects
    • 2025 Patient Summit Prague
    • 2024 Patient Summit Amersfoort
    • 2024 Barcelona Patient Conference
      • About Barcelona 2024
      • Videos Patient Conference Barcelona 2024
      • Videos Talkshows Barcelona 2024
    • 2023 Patient Summit Madrid
    • 2022 Dublin Patient Conference
      • About Dublin 2022
      • Videos Patient Conference Dublin 2022
      • Videos Talkshows Dublin 2022
    • FAIRVASC
    • Rare Revolution Magazine
    • SEE ME. HEAR ME.
    • VOICES
  • Vasculitis
  • Library
  • News
  • About Us
    • Contact us
    • Our Mission
    • A Registered Charity
  • ...

    ALL Vasculitis Diseases

    All vasculitis diseases as described in the 2012 Chapel Hill classification.

    Some VPAGs deal with just one of the specifics diseases or a group of them while others represent the entire Chapel Hill spectrum.

    Patient Advocacy groups

    shg vaskulitis frankfurt

    SHG Frankfurt am Main

    Disease(s):

    ALL Vasculitis Diseases

    SHG Würzburg-Nürnberg

    Disease(s):

    ALL Vasculitis Diseases

    logo-vaskulitida-cz

    Vaskulitida.cz

    Disease(s):

    ALL Vasculitis Diseases

    VASAS

    Disease(s):

    ALL Vasculitis Diseases

    VF logo

    Vasculitis Foundation

    Disease(s):

    ALL Vasculitis Diseases

    Kosapo

    Disease(s):

    ALL Vasculitis Diseases

    AEVASI

    Disease(s):

    ALL Vasculitis Diseases

    Vasculitis Poland

    Disease(s):

    ALL Vasculitis Diseases

    Are you a patient advocacy group ?

    respresenting patients with a primary form of vasculitis ?
    JOIN US !

    Centers of Expertise

    logo -gen-hosp-prague

    Charles University Prague

    MZ Monbijou BERN

    Medizinisches Zentrum Monbijou BERN

    Meander Medical Centre

    Jagiellonian University Medical College

    aumc_logo

    Amsterdam UMC

    mum logo

    Maastricht UMC

    LUMC_Logo

    Leiden UMC

    Humanitas_University

    Humanitas Research Hospital

    Are you a vasculitis expert centre ?

    dealing with one or more forms of a primary vasculitis
    JOIN US !

    News

    FDA warning avacopan

    Update Tavneos Review – April 2026

    5 april, 2026 Geen reacties

    The U.S. Food and Drug Administration (FDA) issued a Drug Safety
    Communication on 31 March 2026, alerting healthcare professionals and patients to serious cases of drug-induced liver injury (DILI) in postmarketing surveillance of avacopan — including cases with fatal outcomes.
    While the FDA operates outside the European regulatory framework,
    its postmarketing findings are directly relevant to the EMA’s ongoing assessment.

    Read More »

    Rare Disease Day 2026

    28 februari, 2026 Geen reacties

    Rare Disease Day is marked every year on the last day of February. On this day, patients, families, healthcare professionals and organisations around the world come together to raise awareness about rare diseases and the people living with them.

    Read More »
    Lungs and ANCA

    ILD and ANCA

    19 februari, 2026 Geen reacties

    A large European multicentre study involving 162 patients provides important new insights into interstitial lung disease (ILD) associated with ANCA antibodies. The findings highlight that lung fibrosis is a serious and often under-recognised complication within the ANCA disease spectrum. One of the key messages emerging from this study is that patients with ANCA-associated ILD should ideally be managed by a multidisciplinary team. Although kidney involvement was common, it did not independently predict mortality. This suggests that lung disease severity at baseline may be the main driver of long-term outcomes in this population.

    Read More »

    collaborate

    join us today 

    Do it Now

    About us

    • We encourage and support Vasculitis Patient Advocacy Groups (VPAGs) to collaborate and grow stronger.
    • If there is no existing VPAG in a particular country we can  help to create one.
    • We collaborate with any institution willing to help us in achieving these goals.

    Find

    VPAGs

    Hospitals

    Countries

    Projects

    Act

    Talk to us

    Join us

    Social Media
    Facebook-f Twitter Google-plus-g Youtube Linkedin-in